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The matrix metalloproteinases (MMPs) are zinc and calci-
um-dependent endopeptidases which belong to the metzincin 
superfamily like the astacins, serralysins, reprolysins, and 
adamalysins or disintegrin metalloproteinases (ADAMs). 
Since its fi rst discovery by Jerome Gross and Charles Lapiere 
in 1962 (Gross and Lapiere, 1962), MMPs have constituted 
a large family of pro-teases. Currently, 24 MMP genes and 
23 MMP proteins have been reported because two iden-tical 
genes in chromosome 1 encode MMP-23. They are a group 
of proteolytic enzymes that are involved in degradation and 
remodeling of extracellular matrix (ECM) and basement mem-
brane proteins. Accumulating evidence, however, suggests 
that MMPs are also participating in a range of physiological 
processes such as infl ammation, immunity, neurite growth 
and bone remodeling through processing bioactive molecules 
including cell surface receptors, apoptotic ligands, pro-neuro-
trophic factors and chemokines/cytokines (Yamamoto et al., 
1999; Lee et al., 2001; Van Lint and Libert, 2007). 
In the central nervous system (CNS), MMPs play a fun-
damental role in CNS development in-cluding neurogenesis, 
myelogenesis, and axonal guidance as well as maintaining 
normal brain functions such as synaptic plasticity, learning 
and memory. The basic biology and roles of MMPs in the CNS 
Matrix metalloproteinases (MMPs) are a subfamily of zinc-dependent proteases that are re-sponsible for degradation and remod-
eling of extracellular matrix proteins. The activity of MMPs is tightly regulated at several levels including cleavage of prodomain, 
allosteric activation, com-partmentalization and complex formation with tissue inhibitor of metalloproteinases (TIMPs). In the 
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sclerosis, ischemia/reperfusion and Parkinson’s disease. We further highlight accumu-lating evidence that MMPs might be the 
culprit in Parkinson’s disease (PD). Among them, MMP-3 appears to be involved in a range of pathogenesis processes in PD 
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Abstract
have been extensively discussed by recent reviews (Yong, 
2005; Agrawal et al., 2008). In this review, we provide an 
overview of the basic biochemical characteristics, regulation 
of activation and biological functions of MMPs, and then dis-
cuss their role in the CNS mainly focusing on brain pathologic 
conditions including neurodegeneration, neuroinfl ammation 
and ischemia.
MODULAR DOMAIN STRUCTURE AND SUBFAMILIES
The MMP members share structural homologies includ-
ing common N-terminal propeptide and catalytic domains. In 
addition, subfamilies are categorized by other domains such 
as fi bro-nectin-like repeats, C-terminal hemopexin-like do-
mains, Ig-like domain and transmembrane domains (Fig. 1). 
All MMPs have an N-terminal signal peptide directing them 
to the secretory pathway. Except membrane-type MMPs (MT-
MMPs), all MMPs are destined to be released into the extra-
cellular space as inactive pro-enzyme forms called zymogens. 
The propeptide domain, consisting of about 80 amino acids, 
has a conserved PRCG (V/N)PD amino acid sequence. The 
cysteine contained within this sequence interacts with zinc 
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MT1 through 6-MMPs and MMP23 belong to this subfamily. 
Three secreted MMPs (MMP-11, -21, -28) and all MT-MMPs 
have a basic RX[K/R]R motif at the C-terminal end of propep-
tide domain which can be cleaved by intracellular furin.
Regulation of MMPs
Since MMPs are able to degrade all the protein constitu-
ents in the extracellular matrix, their pro-teolytic activity has to 
be tightly controlled under normal conditions to prevent tissue 
destruction (Yong et al., 1998). There are the following ways 
to regulate the activity of MMPs: 1) gene tran-scriptional regu-
lation; 2) activation of proenzyme by removing the propeptide 
domain; 3) the in-teraction with tissue inhibitor of metallopro-
teinases (TIMPs); 4) pericellular or intracellular com-partmen-
talization; 5) allosteric activation; 6) oxidative modifi cation. 
Many MMP genes are inducible by a wide variety of effectors 
including growth factors, cytokines such as TNF-α and IL-1β, 
chemical agents, physical stress, oncogen products and inter-
estingly, cell-cell or cell-ECM inte-raction (Ries and Petrides, 
1995; Vincenti, 2001; Vincenti and Brinckerhoff, 2007). Their 
gene ex-pression also can be suppressed by other factors 
such as TGF-β, retinoic acids and glucocorti-coids (Osteen 
et al., 1996; Li et al., 2011; Ye et al., 2011). These external 
effectors trigger the var-ious intracellular signal transduction 
Fig. 1. Domain structure of matrix metalloproteinases family. All MMPs consist of a N-terminal signal peptide and a propeptide domain fol-
lowed by a C-terminal catalytic domain. A propeptide domain contains a cysteine switch which forms complex with catalytic zinc in a catalyt-
ic domain inhibiting their enzymatic activity. MMP-7 and -26 have only the minimal domain. Most of MMPs have a linker (hinge-region) and 
hemopexin like do-main at the C-terminal to a catalytic domain. MMP-11, -21 and -28 have a furin-activating motif, RX[K/R]R, at the C-termi-
nal end of their propeptide domains. Two gelatinases, MMP-2 and -9, contain three fi bronectin II like repeats in the catalytic domains. MMP-
9 is the only MMP which has a heavily O-glycosylated hinge region. All membrane-anchored MMPs contain a furin-activating motif. MT4, -6-
MMPs are anchored to the plasma membrane through GPI-anchor. MT1, -2, -3 and-5-MMPs are bound to the cell membrane through type 
I transmembrane domain while MMP-23 is through type II transmembrane domain. The C-terminal of MMP-23 contains cysteine array (Ca) 
and immunoglobulin (Ig)-like domain replacing hemopexin domain.
in the catalytic domain to suppress its own proteolytic activ-
ity (Cysteine-switch) (Van Wart and Birkedal-Hansen, 1990; 
Becker et al., 1995). The catalytic domain consisting of about 
160-170 amino acids has a HEXXHXXGXXH, catalytic zinc-
binding motif and a conserved methionine, which form a 
unique “Met-turn” struc-ture (Bode et al., 1993). The catalytic 
domain also requires an additional structural zinc and 2 to 3 
calcium ions for the stability and the enzymatic activity. MMP-7 
and -26 consist of this minimal domain, propeptide and cata-
lytic domains. C-terminal structures after catalytic domains 
are much more variable conferring MMPs substrate specifi city 
and the interface for interaction with TIMPs (tissue inhibitor of 
metalloproteinases).  Most MMPs have a linker (hinge region) 
and a hemopexin-like domain in addition to a minimal domain. 
The hinge region of most MMPs consists of 10-30 amino ac-
ids that connects a catalytic domain and a hemopexin-like do-
main. C-terminus hemopexin domain in collagenase (MMP-1, 
interstitial collagenase) is crucial for cleavage of triple helical 
interstitial collagen (Bode, 1995). The two gelatinases (MMP-2 
and MMP-9) have additional three fi bronectin-like repeats in 
their catalytic domain that interact with collagens and gelatins, 
respectively (Allan et al., 1995; Steffensen et al., 1995). Addi-
tionally, MMP-9 has a heavily O-glycosylated hinge region that 
is responsible for fi ne tuning its bioavailability (Van den Steen 
et al., 2006). The membrane-type MMP subfamily has a trans-
membrane domain that anc-hors MMPs to the cell surface. 
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pathways including MAPKs, JAK-STAT or NF-κB pathways 
leading to the induction of MMP genes (Korzus et al., 1997; 
Kheradmand et al., 1998; Reunanen et al., 1998). Although 
the activator protein-1 (AP-1) binding site in the MMP promot-
ers has been considered as a main transcriptional regulator in 
most MMPs (Auble and Brinckerhoff, 1991; Kim et al., 2008; 
Liu et al., 2010; Singh et al., 2010), MMP-8, -11 and -21 are 
lack of AP-1 cis-element in their promoter. Another group of 
promoters of MMP-2, -14, and -28 does not have TATA box 
and are mainly regulated by ubiquitous Sp-1 family of tran-
scriptional factor (Yan and Boyd, 2007).
The MMPs are initially expressed as inactive zymogens 
in which a zinc atom in the catalytic domain interacts with a 
cysteine residue (Cysteine switch) (Van Wart and Birkedal-
Hansen, 1990). Activating factors cause the disruption of the 
Cys-Zn2+ interaction, which renders pro-MMPs par-tially ac-
tive. Then, the partially active enzyme auto-catalyzes the pro-
peptide region and make the enzyme fully active (Van Wart 
and Birkedal-Hansen, 1990). Activation of all MT-MMPs and 
furin-activated MMPs is well characterized intracellular event 
which leads to immediate catalytic activation of MMPs upon 
appearing on the cell surface or secretion. This process is 
achieved by serine proteinase, furin that is localized in the 
trans-Golgi network. Remaining MMPs are se-creted as in-
active zymogens and activated by serine proteinases like 
plasmin or other MMPs (MMP-3 and -14). Plasmin that is acti-
vated from plasminogen by the action of tissue- or urokinase-
plasminogen activator is an important physiologic activator of 
pro-MMPs. Activation of proMMP could be achieved without 
involving proteolytic cleavage of prodomain by the mechanism 
called allosteric activation. Both proMMP-9 and -2 could be 
activated upon binding to their substrates, gelatin or collagen 
IV and α2 chain of collagen VI, respectively (Bannikov et al., 
2002; Freise et al., 2009). Reactive oxygen species (ROS), 
peroxynitrite, glutathione could activate MMPs without remov-
al of prodomains through modifi cation of thiol in their catalytic 
core which lead to disruption of thiol-zinc interaction (Okamoto 
et al., 2001; Gu et al., 2002; McCarthy et al., 2008).
Tissue inhibitors of metalloproteinases (TIMPs) are the en-
dogenous regulators of MMP activ-ities in the tissue (Vincenti, 
2001). Following activation, the activities of MMPs are regu-
lated by the formation of non-covalent complexes with TIMPs. 
Four homologous TIMPs have been iden-tifi ed to date (Yong 
et al., 1998). They have about 190 amino acids with longer 
N-terminal and shorter C-terminal domain. N-terminal domain 
itself is fully functional in terms of inhibition of MMPs by chelat-
ing their catalytic zinc atom. The expression of TIMPs is also 
regulated at the transcriptional level. For example, TIMP-1 
contains AP-1 site in its promoter (Ulisse et al., 1994). This 
implies that the expression of MMPs and TIMPs can be regu-
lated coordinately by the same signal. However, the MMPs 
and TIMPs can also be regulated in opposite patterns. It has 
been shown that TGF-β induces the increased expression of 
TIMP-1 and suppresses collagenase and stromelysin (MMP-
3) expression in fi broblasts and endothelial cells (Edwards et 
al., 1987). Since a number of studies have demonstrated that 
excessive production of MMPs are involved in the pathology 
of many infl ammatory and malignant diseases, the balance 
between the MMPs and their inhibitors is thought to be im-
portant in the maintenance of normal physiologic conditions.
Subcellular localization and regulation
Accumulating evidence suggests that they are localized to 
various intracellular sites including nucleus, cytoplasm and 
mitochondria. Recent studies have identifi ed diverse intra-
cellular sub-strates for MMPs and its novel biological roles. 
Although the molecular mechanisms are poorly understood, 
nuclear localization of MMPs has been widely observed in 
various types of cells including cardiac myocytes, fi broblasts, 
neuronal cells, pulmonary artery endothelial cells and he-
patocytes. Currently nuclear localization of MMP-2, -3, -9, 
-13 and MT1-MMP has been reported. MMP-2 and -3 have 
nuclear localization sequence (NLS) in the C-terminus and 
catalytic domain, respectively (Kwan et al., 2004; Si-Tayeb et 
al., 2006).  Nuclear localization of MMP-2 in cardiac myocytes 
has been observed, highlighting its role in degradation of Poly 
(ADP-ribose) polymerase (PARP) (Kwan et al., 2004). More 
recently, it has been reported that cigarette-smoke induced 
MMP-2 expression in the nucleus of pulmonary artery endo-
thelial cells, causing apoptosis (Aldonyte et al., 2009). In the 
ischemic neurons, increased proteolytic activity of MMP-2 and 
-9 in the ischemic neuronal nuclei at the early phase is respon-
sible for DNA fragmentation after reperfusion. This is caused 
by MMP-mediated degradation of PARP-1 and X-ray cross-
complementary factor 1 (XRCC1) (Yang et al., 2010). Exclu-
sive expression of cleaved active MMP-3 in the nucleus was 
demonstrated, suggesting removal of prodomain is crucial for 
nuclear translocation of MMP-3 (Si-Tayeb et al., 2006). Inter-
estingly, transcription factor-like function of MMP-3 was shown 
in chondrocytes. Binding of nuclear MMP-3 to a transcription 
enhance sequence in the connective tissue growth factor 
(CCN2/CTGF) enhances transcriptional activity CCN2/CTGF 
(Eguchi et al., 2008). Extensive analysis of nuclear MMP-3 
associated proteins (NuMAPs) identifi ed several candidates 
such as HP1γ and NCoR1 whose function on transcrip-tional 
regulation of CCN2/CTGF could be modulated by MMP-3. 
Nuclear localization of MMP-13 was also reported in oxygen 
and glucose deprived neuronal cells and after cerebral isch-
emia of rats and humans (Cuadrado et al., 2009). Both MMP-2 
and MT1-MMP was observed in the nuc-leus of hepatocel-
lular carcinoma (HCC) and aggressiveness of HCC including 
poor prognosis and large tumor expands was associated with 
nuclear localization of MT1-MMP (Ip et al., 2007).
Increasing number of studies indicate that various MMPs 
have been also found in the cytosol. We have recently dem-
onstrated that active MMP-3 is expressed in the cytosol of do-
paminergic cells and plays role in apoptosis and is involved in 
cleavage of α-synuclein and DJ-1, modulating their functions 
(Choi et al., 2008; Choi et al., 2011a; Choi et al., 2011b). This 
will be discussed more in detail later in this review. Mitochon-
drial localization and perinuclear accumulation of MMP-1 was 
shown in epithelial cells conferring resistance to apoptosis 
(Limb et al., 2005). Intra-cellular role of MMP-2 has been high-
lighted in acute myocardial ischemia and reperfusion model 
demonstrating that MMP-2 is responsible for cleavage of tro-
ponin I (TnI), the contractile protein regulatory element, and 
the cytoskeletal protein α-actinin. Peroxynitrite is a key me-
diator for the activation of MMP-2 in this model (Wang et al., 
2002a; Wang et al., 2002b; Sung et al., 2007). Another exam-
ple is MMP-26 which is mainly retained inside cells despite of 
its N-terminal signal peptide. Prodomain of MMP-26 contains 
a unique motif, PHCGVPD, that is assumed to in-crease au-
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tocatalytic activity leading intracellular activation (Marchenko 
et al., 2004). 
MMPs in the Central Nervous System (CNS)
A range of MMPs play multiple roles in the development 
of the CNS, maintaining normal physiological functions, re-
covery after injury and the pathogenesis of brain diseases. 
During development of the CNS, various MMPs and TIMPs 
are expressed in various types of cells including neurons, as-
trocytes, oligodendrocytes and microglia, being involved in 
neurogenesis, axonal guidance, angiogenesis and myelino-
genesis (Cañete Soler et al., 1995; Vaillant et al., 2003; Larsen 
et al., 2006). In the adult brain, MMPs are likely involved in a 
range of pivotal processes like migration of neurons and glia, 
synaptic plasticity, learning and memory, myelin turnover and 
angiogenesis through extracellular matrix (ECM) remodeling 
(Szklarczyk et al., 2002; Meighan et al., 2006; Ogier et al., 
2006; Bozdagi et al., 2007). They are also important in the 
repair of adult brain after injuries such as spinal cord injury 
and stroke (Larsen et al., 2003; Lee et al., 2006). The normal 
functions of MMPs in the CNS were extensively discussed in 
the recent review by Agrawal et al. (2008). 
MMPs in Neurodegenerative diseases
Recently, an increasing amount of evidence suggests that 
MMPs may play an crucial role in the pathogenesis of sev-
eral neurodegenerative disorders including multiple sclerosis, 
Alzheimer’s disease, Parkinson’s disease, malignant glioma, 
neuroinfl ammation and ischemia (Forsyth et al., 1999; Lorenzl 
et al., 2002; Lorenzl et al., 2003; Yong et al., 2007; Candelario-
Jalil et al., 2009; Choi et al., 2011b; Shin et al., 2012).
The roles for MMPs in the pathogenesis of multiple sclero-
sis (MS) have been widely studied. MS is a brain infl ammatory 
disorder demonstrating destruction of myelin sheath in the 
brain and spinal cord. Infi ltration of various types of periph-
eral immune cells such as T cell, dendritic cells and monocyte/
macrophages into the brain parenchyma accompanied with 
breakdown of blood-brain barrier (BBB) are major pathologic 
characteristics of MS. Upon entering in the CNS,  they result 
in severe destruction of myelin and axon in cooperation with 
parenchymal resident cells including astrocytes and microglia. 
Alterations of various MMPs like MMP-1, -2, -3, -7, -9, -12, -13, 
-14 and -19 have been reported in MS. The MMPs were de-
tected in the cerebrospinal fl uid (CSF) of patients with MS or its 
animal model, experimental allergic encephalomyelitis (EAE) 
(Yushchenko et al., 2000; Fainardi et al., 2009). MMP-9 has 
been most extensively studied among them. Enhanced ex-
pression of both MMP-7 and -9 in parenchymal macrophages 
and small blood vessels were demonstrated in postmortem 
human MS brain (Cossins et al., 1997). The ratio of MMP-9/
TIMP-1 in serum was elevated in relapsing-remitting MS pa-
tients and is cor-related with increase in positive MRI lesions 
(Waubant et al., 1999). In EAE model, it has been shown that 
MMP-9 plays a key role in BBB disruption and traffi cking of 
leukocytes into the brain parenchyma (Agrawal et al., 2006). 
Higher level of MMP-2 in serum and CSF of MS patients was 
also reported (Avolio et al., 2003; Benesová et al., 2009). The 
increased expressions of MMPs were shown in microglia and 
astrocytes in the brain lesions of MS patients (Cuzner et al., 
1996; Maeda and Sobel, 1996). In animal studies, the applica-
tion of several MMP inhibitors elicit reduced symptoms and 
severity of EAE (Hewson et al., 1995). The molecular mecha-
nisms of MMPs in the pathogenesis of MS include the direct 
destruction of myelin protein, BBB disruption and chemokine/
cytokine activation. Myelin protein could be a direct proteo-
lytic substrate for MMPs. Activated leukocytes from peripheral 
blood or CNS resident cells could release MMPs which  tar-
get myelin protein resulting in fragments. Fragmented myelin 
protein further activate neighboring immune cells releasing 
MMPs. This forms a vicious loop for activation/destruction 
leading to demyelinated axons (Starckx et al., 2003; Opde-
nakker et al., 2006; Candelario-Jalil et al., 2009). MMP-me-
diated cleavage of cytokines/chemokines and its role in im-
mune modulation have been investigated in MS patients and 
EAE model (Sellebjerg and Sørensen, 2003). MMPs are also 
involved in the conversion of pro-TNF-α to mature secreted 
protein and blood-brain barrier (BBB) disruption (Gearing et 
al., 1994; Gasche et al., 2001). 
The role of MMPs in cerebral ischemia and stroke was 
also investigated both in animal mod-els and human stroke. 
Dual roles of MMPs have been observed after brain ischemia: 
propagat-ing neuronal death and apoptosis at the early phase 
of injury through disruption of ECM and opening the BBB; 
late-phase repairing by promoting angiogenesis and neuro-
genesis. At the early stage after stroke, transient activity of 
MMP-2 which is responsible for reversible opening of the BBB 
has been reported in rodent and non-human primates (Chang 
et al., 2003; Yang et al., 2007). Tight junction protein, claudin-5 
is degraded by MMP-2. MMP-9 is activated and implicated in 
more extensive cerebral vascular damage at the later phase. 
Thus, early intervention within 3 h post reperfusion with MMP 
inhibitors showed the prevention of BBB disruption (Yang et 
al., 2007).  In addition, cerebral infarct size was signifi cantly 
reduced by treatment with MMP inhibitors or in MMP-9 knock-
out but not in MMP-2 knockout mice (Asahi et al., 2000; Asahi 
et al., 2001). Interestingly, NO produced in cerebral ischemia 
and reperfusion can activate pro-MMP-9 by S-nitrosylation 
which in turn, causes direct neuronal apoptosis (Gu et al., 
2002). In reperfusion injury following ischemia in rat brain, the 
expression of MMP-3 is induced in both microglia and apop-
totic neurons and it is suggested that MMP-3 may play an im-
portant role in disrupting the BBB together with other MMPs 
such as MMP-2 and -9 (Rosenberg et al., 2001).
Malignant gliomas are the most common malignant brain 
tumors that are extremely invasive. The strong correlation be-
tween the invasiveness of glioma cells and MMPs such as 
MMP-2, MMP-9 and MT-MMPs has been shown both in vitro 
and in vivo (Rao et al., 1996; Uhm et al., 1996; Yamamoto 
et al., 1996). The expression of MMPs are up-regulated  in 
many gliomas (Forsyth et al., 1999). In contrast to MMPs, the 
expression of TIMP-1 and -2 is decreased, sug-gesting disrup-
tion of the balance between MMPs and their inhibitors may 
contribute to pathology of malignant gliomas (Mohanam et al., 
1995). It was also shown that MMPs inhibitor induces apopto-
sis of malignant gliomas (Yoshida et al., 2003). MMP-9 plays a 
key role in regulating in-vasiveness of malignant glioma cells 
and invasiveness is  largely attributed to the poor prognosis. 
Recent study indentifi ed miRNAs, miR-491-5p, as a direct 
regulator of  MMP-9 expression in U251 and U87 glioma cells, 
demonstrating that  miR-491-5p reduces MMP-9 expression 
137
Kim and Joh.   Matrix Metalloproteinases in Neurodegenerative Diseases
www.biomolther.org
and  inhibits cellular invasion (Yan et al., 2011). Recently, oth-
er MMPs like MMP-1, -11 and -19 were appeared to be of im-
portance for the development of high-grade astrocytic tumor 
and may be promising targets for therapy (Stojic et al., 2008).
Alzheimer’s disease (AD) is the most common neurodegen-
erative disease that accounts for 50-80% of dementia. Patho-
logically, AD is characterized by gross atrophy of affected 
cerebral cortex resulted from neuronal loss and synaptic de-
generation. The temporal, parietal lobe and parts of the frontal 
cortex and cingulate gyrus are most widely affected (Wenk, 
2003). The presence of extracellular amyloid plaques and 
intracellular neurofi brillary tangles is the most charac-teristic 
pathologic feature of AD (Tiraboschi et al., 2004). Extracellular 
plaques consist of about 40 amino-acid long small peptides 
called beta-amyloid (Aβ). Aβ is generated by enzymatic cleav-
age of amyloid precursor protein (APP), a transmembrane 
protein. The process involved in proteolytic cleavage of APP 
is still waiting for elucidation. One of these fragments, Aβ1-
42, gives rise to fi brils of Aβ, which further aggregates outside 
neurons in dense masses of protein known as senile plaques 
(Ohnishi and Takano, 2004; Tiraboschi et al., 2004). It has 
been shown that MMPs play a dual role in the pathogenesis of 
AD. MMPs may directly de-grade Aβ resulting in reduction in 
Aβ deposit (Yan et al., 2006; Miners et al., 2008). On the other 
hand, MMPs such as MMP-2, -3 and -9 could be induced by 
Aβ in microglia, astrocytes or vas-cular smooth muscle cells 
contributing to brain parenchymal destruction.  MMP-9 is over-
expressed in AD brain tissue compared to controls and it can 
degrade synthetic 40-residue long Aβ protein in vitro (Back-
strom et al., 1992; Roher et al., 1994). MMP-2 has also been 
shown to degrade 40- to 42-residue long Aβ purifi ed from AD 
brain tissue (Roher et al., 1994). In AD brains, MMP-3 is ex-
pressed predominantly in brain white matter. Double immuno-
staining of MMP-3 and GFAP in the white matter suggests 
that astrocytes may be a major source of MMP-3 in AD brain 
(Yoshiyama et al., 2000). MMP-3 immunoreactivity was also 
detected in the interstitium between myelinated axons and se-
nile plaques of patients with AD (Yoshiyama et al., 2000). It 
has been also demonstrated that Aβ1-42 induces MMP-3, -12 
and -13 expressions in microglia in PI3K-dependent manner 
(Ito et al., 2007). Recent analysis of CSF from AD patients 
indicated that MMP-3 is signifi cantly elevated while MMP-2 
is decreased (Horstmann et al., 2010). These data suggest 
that MMPs may be involved in the processing of APP and the 
pathogenesis of AD.
Parkinson’s disease (PD) is the second most common neu-
rodegenerative disorders characterized by motor symptoms 
including resting tremor, rigidity, bradykinesia and postural in-
stability resulting from selective degeneration of dopaminergic 
neurons in the substantia nigra pars compacta. Accumulating 
evidence suggests MMPs as a major culprit in the pathogen-
esis of PD. Expression of MMPs such as MMP-1, -2 and -9 as 
well as TIMP-1 and -2 in the substantia nigra (SN) of postmor-
tem PD brain tissue was fi rst reported by Lorenzl et al. show-
ing alterations in MMP-2 and TIMP-1 in the SN of PD patients 
(Lorenzl et al., 2002). Since then, a number of studies includ-
ing our own have demonstrated that MMPs are implicated in a 
range of pathophysiological processes of PD such as microg-
lial activation, infl ammation, direct dopaminergic apopto-sis, 
disruption of the BBB and modulation of α-synuclein pathol-
ogy by cleavage (Kim et al., 2005; Choi et al., 2008; Joo et al., 
2010; Kim and Hwang, 2011).   
MMP-3 AND PARKINSON’S DISEASE
MMP-3 was fi rst noted as a neutral proteinase in human 
cartilage in 1974 (Sapolsky et al., 1974) and in rabbit bone 
fi broblast culture (Werb and Reynolds, 1974). The name 
‘stromelysin’ was introduced by Chin et al. (1985), but it has 
also been named ‘transin’ and ‘collagenase activating pro-
tein’ (Chin et al., 1985; Matrisian et al., 1985; Treadwell et al., 
1986). MMP-3 has a broad spectrum of substrates such as 
collagens, gelatin, elastin, laminin, casein, fi bronectin, α1-AT, 
MBP and TNF-α precursor (Chandler et al., 1997). In addition, 
MMP-3 also can play a central role in the cleavage of other 
pro-form of MMPs including MMP-1, -2, -7, -8, -9, -13 leading 
to active forms (Chandler et al., 1997). MMP-3 has been impli-
cated in infl ammatory dis-orders including rheumatoid arthritis 
(RA), multiple sclerosis and AD (Zucker et al., 1994; Maeda 
and Sobel, 1996; Yoshiyama et al., 2000). MMP-3 levels are 
signifi cantly in-creased both in serum and synovial fl uid in RA 
patients (Zucker et al., 1994; Ishiguro et al., 1996). Serum 
MMP-3 levels are decreased by anti-TNF-α therapy in RA, 
suggesting that TNF-α may induce MMP-3 expression (Ca-
trina et al., 2002). It has also been shown that MMP-3 levels in 
synovial fl uid (SF) are signifi cantly related with the concentra-
tion of soluble FasL (sFasL) in SF of patients with RA, which 
indicates that MMP-3 may regulate the shedding of FasL 
(Matsuno et al., 2001). The role of MMP-3 as a mediator of 
neuroinfl ammation responsible for dopaminergic neuronal de-
generation was demonstrated. Active MMP-3 is released from 
neurons undergoing apoptosis after stress. Then it activates 
microglia to secrete pro-infl ammatory cytokines such as IL-
1β, TNF-α and IL-6 as well as reactive oxygen species (ROS) 
that subsequently cause neighboring neuronal death. NNGH, 
a specifi c inhibitor of MMP-3, largely attenuates microglial 
activation and neuronal death (Kim et al., 2005). MMP-3 is 
also involved in LPS-mediated microglial activation. MMP-3 
and -9 are responsible for mitogen-activated protein kinases 
(MAPKs)- and NF-κB-mediated proinfl ammatory cytokines re-
lease from LPS-stimulated microglia (Woo et al., 2008).
Expression and activity of MMP-3 have been shown in a 
range of rodent PD models and postmortem PD brain. In-
crease in MMP-3 expression in the SN was observed in ro-
dent model of PD, rats injected with 6-hydroxydopamine (6-
OHDA) (Sung et al., 2005). Recent study showed that MMP-3 
is expressed in Lewy bodies (LBs), a pathologic hallmark of 
PD (Choi et al., 2011b). Increased immunoreactivity of MMP-3 
was also observed in tyrosine hydroxylase (TH)-positive dopa-
minergic neurons in the SN of mice administered with MPTP 
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a selective dopa -
minergic neurotoxin. In this study, signifi cant reductions in 
MPTP-mediated dopaminergic neuronal degeneration as well 
as microglial activation were observed in MMP-3 knockout 
mice suggesting that MMP-3 is a key player in dopaminer-
gic neuronal degeneration (Kim et al., 2007). Rat injected with 
LPS in the SN shows microglial acti-vation and dopaminergic 
neuronal degeneration. In this model, MMP-3 expression in 
the SN was signifi cantly increased 24 h and 48 h after LPS in-
jection (McClain et al., 2009).  In contrary to the general belief 
that the inactive proform of MMP3 is activated in extracellular 
space, emerging evidence implies the existence of a mecha-
nism of intracellular activation of MMP-3. Under apoptotic 
stress, MMP-3 is induced and generates the proform which 
is subsequently cleaved to the catalytically active MMP-3 by a 
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serine protease other than furin. Intracellular enzymatic activ-
ity of MMP-3 is directly responsible for apoptosis of dopami-
nergic cells (Choi et al., 2008). Recently, intracellular targets 
for MMP-3 that are clearly linked to the pathogenesis of PD 
have been investigated (Sung et al., 2005; Choi et al., 2011a; 
Choi et al., 2011b). Mutations in SNCA that encodes α-synu-
clein were the fi rst reported genetic cause in familiar forms of 
PD (Polymeropoulos et al., 1997). Later, α-synuclein aggre-
gates were identifi ed as the major com-ponent in Lewy bodies 
(LB), intracellular protein inclusions, a pathologic hallmark of 
PD (Spillantini et al., 1997). α-synuclein is cleaved by MMP-
3 generating fragmented peptides that forms more toxic ag-
gregates than the intact α-synuclein. MMP3-cleaved species 
(N-terminal) in extra-cellular space were cytotoxic when they 
were added to the cell culture media (Sung et al., 2005). The 
presence of C-terminally truncated α-synuclein has been re-
ported in Lewy bodies of sporadic PD and Lewy body demen-
tia (Baba et al., 1998; Liu et al., 2005). C-terminal truncation 
is also observed preferentially in A53T transgenic mice show-
ing motor symptoms (Lee et al., 2002). Various lengths of the 
truncated forms of α-synuclein were reported (Li et al., 2005; 
Liu et al., 2005). About 15% of α-synuclein in Lewy bodies is 
truncated forms and incomplete degradation produced highly 
amyloidogenic fragments (Baba et al., 1998; Campbell et al., 
2001). More recently, it has been shown that MMP-3 cleaves 
WT and mutant α-synuclein generating slightly different frag-
mented peptide profi les. MMP-3 gives rise to C-terminally 
truncated peptides of amino acids 1-78, 1-91, and 1-93 and 
that A53T mutant α-synuclein generates signifi cant in-crease 
of these peptides. Both in vivo and in vitro experiments shows 
that these peptides cause stronger dopaminergic neuronal 
death compared to the intact α-synuclein despite less aggre-
gation formation (Choi et al., 2011b). The results suggest that 
MMP-3 could modulate the aggrega-tion property of α-synu-
clein contributing to the pathogenesis of PD. In addition, DJ-1 
is also fragmented by MMP-3. DJ-1 is a protein belonging 
to ThiJ/PfpI/DJ-1 superfamily. Two mutations were identifi ed 
within the DJ-1 gene in two families linked to the recessive 
PD PARK7 locus (Bonifati et al., 2003). One is a chromosomal 
deletion of 4 kb leading to the absence of DJ-1 expression, 
while the other is a L166P point mutation in which a highly 
conserved leucine was substituted for a proline. The latter de-
stabilizes DJ-1 protein and promotes its degradation through 
the ubiquitin-proteasomal system (Miller et al., 2003). Active 
MMP-3 cleaves DJ-1 caus-ing impairment of its antioxidant 
function. While MPTP administration signifi cantly diminished 
Fig. 2. The role of MMP-3 in the pathogenesis of Parkinson’s disease. Emerging evidence suggests that MMP-3 plays a key role in dopa-
minergic neuronal degenera-tion. Under stress conditions, MMP-3 is induced in dopaminergic neurons generating proMMP-3. Activation of 
MMP-3 might be achieved in cytoplasm as well as extracellular space. Catalytically active MMP-3 (actMMP-3) triggers microglial activation 
resulting in release of proinfl ammatory cytokine such as IL-1β, TNF-α and IL-6. Microglial substrates for act MMP-3 and signaling event 
leading to microglial activation are yet to be elucidated. NADPH oxidase (NOX2)-mediated ROS generation was also observed in microg-
lia treated with actMMP-3. In addition, MMP-3 could be also activated intracellularly by unknown serine proteases upon stress such as 
6-OHDA or MPP+, a selective dopaminergic toxin. Activated MMP-3 could cleave α-synuclein into several fragments by C-terminal trunca-
tion. These fragmented peptides are prone to aggregate and re-sult in increased cytotoxicity. MMP-3 could also degrade DJ-1 and impair its 
antioxidant function resulting in increased oxidative stress. Intracellular actMMP-3 is directly linked apoptotic path-way in dopaminergic cells 
as well. 
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DJ-1 expression in the SN of mice, its degradation was largely 
attenuated in MMP-3 knockout mice. This study suggests that 
cleavage of DJ-1 by the intracellular MMP-3 in response to 
cell stress impairs the protective role of DJ-1 against oxidative 
damage (Choi et al., 2011a). The proposed roles of MMP-3 in 
the pathogenesis of PD is illustrated in Fig. 2.
MMP inhibitors and Neuronal disorders
As emerging evidence indicates MMPs as a major culprit 
for a number of disease conditions including cancers, infl am-
mation and neurodegenerative disorders, the importance of 
MMPs as a therapeutic target has been highlighted. MMP in-
hibitors could be categorized into two groups, macromolecular 
inhibitors such as TIMPs and monoclonal antibodies and small 
molecules including natural and synthetic inhibitors (Sang et 
al., 2006; Hu et al., 2007). TIMPs are the most thoroughly stud-
ied natural MMP inhibitors. Physiological balance between 
MMPs and TIMPs are considered important to prevent mul-
tiple disease conditions. Long-chain fatty acids, epigal-locate-
chin gallate (EGCG) extracted from green tea and fl avonoids 
also belong to natural MMP inhibitors. Since the fi rst endeavor 
to develop smallmolecule MMP inhibitors for the treatment of 
arthritis, a number of synthetic MMP inhibitors have been test-
ed for various diseases over the past three decades. The fi rst 
generation of synthetic MMP inhibitors was designed based 
on mimicking natural peptide substrates, thus so called pep-
tidomimetic MMP inhibitors. Later on, structure-based MMP 
inhibitors with a zinc-binding group (ZBG), a backbone that 
chelates zinc ion in the catalytic core of MMPs, have been 
extensively developed and tested. Four major ZBGs have 
been exploited for the development of MMP inhibitors: car-
boxylates, thiolates, phosphinyls and hydroxamates. Of these, 
hydroxamates-based MMP inhibitors have been stu-died most 
widely. A ZBG of hyroxamate acts as a bidentate ligand with 
the catalytic zinc ion and it also forms hydrogen bonds with 
enzyme backbones, resulting in potent inhibitory effect. Bati-
mastat is one of the fi rst generation of broad-spectrum hydrox-
amates inhibitors. Because of the similarity of catalytic core 
structure between MMPs, it has been challenging to develop 
highlyselective MMP inhibitors. As crystallographic structures 
of more MMPs were revealed, the nextgeneration MMP inhibi-
tors with greater target selectivity were designed. Prinomastat 
is a second-generation hydroxamates MMP inhibitor that has 
much higher IC50 value against MMP-1 and -7 (Sang et al., 
2006). Due to their numerous normal physiological functions 
including tissue remodeling, repression of tumor angiogen-
esis and inactivation of chemokines, therapeutic inhi-bitions 
of MMPs have potential to accompany side effects. Muscu-
loskeletal syndrome (MSS) is the most common side effect 
caused by many MMP inhibitors, which is characterized by 
joint pain, stiffness and tendinitis (Cho et al., 2006). Despite 
the effort toward developing MMP inhibi-tors with high selec-
tivity and therapeutic effi cacy, tetracycline derivative, doxycy-
cline, remains the only FDA approved MMP inhibitor (Hu et al., 
2007). In spite of their low potency, non-hydroxamates MMP 
inhibitors containing other ZBGs such as carboxylates with 
greater target specifi city have been developed (Walker and 
Rosenberg, 2010).
It has been reported that MMP inhibitors bring about ben-
efi cial effects in animal studies of multiple sclerosis, vascular 
dementia, meningitis, Guillain-Barre syndrome and stroke. Of 
these, MMP inhibitors have been most intensively tested in 
acute cerebral ischemia. Studies on mo-noclonal antibodies 
against MMPs and broad spectrum MMP inhibitors such as 
GM-6001, BB-94 and BB-1101 demonstrate that BBB damage, 
infarct volume and neuronal death are signifi cantly reduced by 
MMP inhibitions (Romanic et al., 1998; Gu et al., 2005). As 
discussed, MMPs have a dual role after stroke, aggravating 
neuronal damage at the early phase and tissue repair at the 
later stage, suggesting that short-term administration during 
the early stage would be effective. Patients with MS treated 
with minocycline, tetracycline derivative, demonstrate reduced 
number of gadolinium-enhancing lesions on MRI (Metz et al., 
2004). In EAE, MMP inhibitors reduce damage to the BBB and 
low-dose tetracycline administration with interferon-beta effec-
tively reduces infl ammation (Giuliani et al., 2005). In vascular 
cognitive impairment which is charac-terized by progressive 
white matter damage cause by ischemic injury or hypoxic 
hypoperfusion, MMP inhibitors reduce white matter damage 
(Cho et al., 2006; Walker and Rosenberg, 2010). Use of MMP 
inhibitors in the treatment of AD is controversial since they are 
involved in the genera-tion of Aβ from APP as well as clear-
ance of Aβ As discussed earlier, a couple of MMPs, especially 
MMP-3, play crucial roles in the pathogenesis of PD, suggest-
ing that MMP inhibitors might ameliorate dopaminergic neuro-
nal degeneration.    
CONCLUSION
In this review, we discuss general structure, activation, reg-
ulation and functions of MMPs and subtilize their roles in the 
CNS. Finally, we emphasize on the implication of MMPs in a 
range of neurodegenerative conditions. Based on an increas-
ing number of studies, we further discuss the link between 
MMP-3 and the pathogenesis of PD. Lastly, current status on 
development of MMP inhibitors for treatment of neurodegen-
erative diseases is discussed. We are anticipating much more 
exciting works that potentially lead to therapeutic interventions 
for various brain disorders.
 
REFERENCES
Agrawal, S., Anderson, P., Durbeej, M., van Rooijen, N., Ivars, F., Op-
denakker, G. and Sorokin, L. M. (2006) Dystroglycan is selectively 
cleaved at the parenchymal basement membrane at sites of leuko-
cyte extravasation in experimental autoimmune encephalomyelitis. 
J. Exp. Med. 203, 1007-1019. 
Agrawal, S. M., Lau, L. and Yong, V. W. (2008) MMPs in the central 
nervous system: where the good guys go bad. Semin. Cell Dev. 
Biol. 19, 42-51. 
Aldonyte, R., Brantly, M., Block, E., Patel, J. and Zhang, J. (2009) 
Nuclear localization of active matrix metalloproteinase-2 in ciga-
rette smoke-exposed apoptotic endothelial cells. Exp. Lung Res. 
35, 59-75.
Allan, J. A., Docherty, A. J., Barker, P. J., Huskisson, N. S., Reynolds, 
J. J. and Murphy, G. (1995) Binding of gelatinases A and B to type-I 
collagen and other matrix components. Biochem. J. 309, 299-306.
Asahi, M., Asahi, K., Jung, J. C., del Zoppo, G. J., Fini, M. E. and Lo, 
E. H. (2000) Role for matrix metalloproteinase 9 after focal cerebral 
ischemia: effects of gene knockout and enzyme inhibition with BB-
94. J. Cereb. Blood Flow Metab. 20, 1681-1689.
Asahi, M., Sumii, T., Fini, M. E., Itohara, S. and Lo, E. H. (2001) Matrix 
metalloproteinase 2 gene knockout has no effect on acute brain 
140
Biomol  Ther 20(2), 133-143 (2012)
http://dx.doi.org/10.4062/biomolther.2012.20.2.133
injury after focal ischemia. Neuroreport. 12, 3003-3007.
Auble, D. T. and Brinckerhoff, C. E. (1991) The AP-1 sequence is nec-
essary but not suffi cient for phorbol induction of collagenase in fi -
broblasts. Biochemistry. 30, 4629-4635.
Avolio, C., Ruggieri, M., Giuliani, F., Liuzzi, G. M., Leante, R., Riccio, 
P., Livrea, P. and Trojano, M. (2003) Serum MMP-2 and MMP-9 are 
elevated in different multiple sclerosis subtypes. J. Neuroimmunol. 
136, 46-53.
Baba, M., Nakajo, S., Tu, P. H., Tomita, T., Nakaya, K., Lee, V. M., 
Trojanowski, J. Q. and Iwatsubo, T. (1998) Aggregation of alpha-
synuclein in Lewy bodies of sporadic Parkinson's disease and de-
mentia with Lewy bodies. Am. J. Pathol. 152, 879-884.
Backstrom, J. R., Miller, C. A. and Tökés, Z. A. (1992) Characterization 
of neutral proteinases from Alzheimer-affected and control brain 
specimens: identifi cation of calcium-dependent metalloproteinases 
from the hippocampus. J. Neurochem. 58, 983-992.
Bannikov, G. A., Karelina, T. V., Collier, I. E., Marmer, B. L. and Gold-
berg, G. I. (2002) Substrate binding of gelatinase B induces its en-
zymatic activity in the presence of intact propeptide. J. Biol. Chem. 
277, 16022-16027. 
Becker, J. W., Marcy, A. I., Rokosz, L. L., Axel, M. G., Burbaum, J. 
J., Fitzgerald, P. M., Cameron, P. M., Esser, C. K., Hagmann, W. 
K., Hermes, J. D. and Springer, J. P. (1995) Stromelysin-1: three-
dimensional structure of the inhibited catalytic domain and of the 
C-truncated proenzyme. Protein Sci. 4, 1966-1976.
Benesová, Y., Vasku, A., Novotná, H., Litzman, J., Stourac, P., 
Beránek, M., Kadanka, Z. and Bednarík, J. (2009) Matrix metallo-
proteinase-9 and matrix metalloproteinase-2 as biomarkers of vari-
ous courses in multiple sclerosis. Mult. Scler. 15, 316-322. 
Bode, W. (1995) A helping hand for collagenases: the haemopexin-like 
domain. Structure. 3, 527-530.
Bode, W., Gomis-Rüth, F. X. and Stöckler, W. (1993) Astacins, ser-
ralysins, snake venom and matrix metalloproteinases exhibit iden-
tical zinc-binding environments (HEXXHXXGXXH and Met-turn) 
and topologies and should be grouped into a common family, the 
'metzincins'. FEBS Lett. 331, 134-140.
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., 
Krieger, E., Dekker, M. C., Squitieri, F., Ibanez, P., Joosse, M., van 
Dongen, J. W., Vanacore, N., van Swieten, J. C., Brice, A., Meco, 
G., van Duijn, C. M., Oostra, B. A. and Heutink, P. (2003) Mutations 
in the DJ-1 gene associated with autosomal recessive early-onset 
parkinsonism. Science. 299, 256-259. 
Bozdagi, O., Nagy, V., Kwei, K. T. and Huntley, G. W. (2007) In vivo 
roles for matrix metalloproteinase-9 in mature hippocampal synap-
tic physiology and plasticity. J. Neurophysiol. 98, 334-344. 
Campbell, B. C., McLean, C. A., Culvenor, J. G., Gai, W. P., Blum-
bergs, P. C., Jäkälä, P., Beyreuther, K., Masters, C. L. and Li, Q. X. 
(2001) The solubility of alpha-synuclein in multiple system atrophy 
differs from that of dementia with Lewy bodies and Parkinson's dis-
ease. J. Neurochem. 76, 87-96.
Candelario-Jalil, E., Yang, Y. and Rosenberg, G. A. (2009) Diverse 
roles of matrix metalloproteinases and tissue inhibitors of metal-
loproteinases in neuroinfl ammation and cerebral ischemia. Neuro-
science. 158, 983-994. 
Cañete Soler, R., Gui, Y. H., Linask, K. K. and Muschel, R. J. (1995) 
MMP-9 (gelatinase B) mRNA is expressed during mouse neuro-
genesis and may be associated with vascularization. Brain Res. 
Dev. Brain Res. 88, 37-52.
Catrina, A. I., Lampa, J., Ernestam, S., af Klint, E., Bratt, J., Klareskog, 
L. and Ulfgren, A. K. (2002) Anti-tumour necrosis factor (TNF)-al-
pha therapy (etanercept) down-regulates serum matrix metallopro-
teinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatol-
ogy (Oxford). 41, 484-489.
Chandler, S., Miller, K. M., Clements, J. M., Lury, J., Corkill, D., An-
thony, D. C., Adams, S. E. and Gearing, A. J. (1997) Matrix me-
talloproteinases, tumor necrosis factor and multiple sclerosis: an 
overview. J. Neuroimmunol. 72, 155-161.
Chang, D. I., Hosomi, N., Lucero, J., Heo, J. H., Abumiya, T., Mazar, A. 
P. and del Zoppo, G. J. (2003) Activation systems for latent matrix 
metalloproteinase-2 are upregulated immediately after focal cere-
bral ischemia. J. Cereb. Blood Flow Metab. 23, 1408-1419.
Chin, J. R., Murphy, G. and Werb, Z. (1985) Stromelysin, a connective 
tissue-degrading metalloendopeptidase secreted by stimulated 
rabbit synovial fi broblasts in parallel with collagenase. Biosynthe-
sis, isolation, characterization, and substrates. J. Biol. Chem. 260, 
12367-12376.
Cho, K. O., La, H. O., Cho, Y. J., Sung, K. W. and Kim, S. Y. (2006) Mi-
nocycline attenuates white matter damage in a rat model of chronic 
cerebral hypoperfusion. J. Neurosci. Res. 83, 285-291.
Choi, D. H., Hwang, O., Lee, K. H., Lee, J., Beal, M. F. and Kim, Y. 
S. (2011a) DJ-1 cleavage by matrix metalloproteinase 3 mediates 
oxidative stress-induced dopaminergic cell death. Antioxid. Redox. 
Signal. 14, 2137-2150. 
Choi, D. H., Kim, Y. J., Kim, Y. G., Joh, T. H., Beal, M. F. and Kim, 
Y. S. (2011b) Role of matrix metalloproteinase 3-mediated alpha-
synuclein cleavage in dopaminergic cell death. J. Biol. Chem. 286, 
14168-14177.
Choi, D. H., Kim, E. M., Son, H. J., Joh, T. H., Kim, Y. S., Kim, D., 
Flint Beal, M. and Hwang, O. (2008) A novel intracellular role of 
matrix metalloproteinase-3 during apoptosis of dopaminergic cells. 
J. Neurochem. 106, 405-415. 
Choi, D. H., Kim, E. M., Son, H. J., Joh, T. H., Kim, Y. S., Kim, D., 
Flint Beal, M. and Hwang, O. (2008) A novel intracellular role of 
matrix metalloproteinase-3 during apoptosis of dopaminergic cells. 
J. Neurochem. 106, 405-415. 
Cossins, J. A., Clements, J. M., Ford, J., Miller, K. M., Pigott, R., Vos, 
W., Van der Valk, P. and De Groot, C. J. (1997) Enhanced expres-
sion of MMP-7 and MMP-9 in demyelinating multiple sclerosis le-
sions. Acta. Neuropathol. 94, 590-598.
Cuadrado, E., Rosell, A., Borrell-Pagès, M., García-Bonilla, L., 
Hernández-Guillamon, M., Ortega-Aznar, A. and Montaner, J. 
(2009) Matrix metalloproteinase-13 is activated and is found in the 
nucleus of neural cells after cerebral ischemia. J. Cereb. Blood 
Flow Metab. 29, 398-410. 
Cuzner, M. L., Gveric, D., Strand, C., Loughlin, A. J., Paemen, L., Op-
denakker, G. and Newcombe, J. (1996) The expression of tissue-
type plasminogen activator, matrix metalloproteases and endog-
enous inhibitors in the central nervous system in multiple sclerosis: 
comparison of stages in lesion evolution. J. Neuropathol. Exp. 
Neurol. 55, 1194-1204.
Edwards, D. R., Murphy, G., Reynolds, J. J., Whitham, S. E., Docherty, 
A. J., Angel, P. and Heath, J. K. (1987) Transforming growth factor 
beta modulates the expression of collagenase and metalloprotein-
ase inhibitor. EMBO J. 6, 1899-1904.
Eguchi, T., Kubota, S., Kawata, K., Mukudai, Y., Uehara, J., Ohgawara, 
T., Ibaragi, S., Sasaki, A., Kuboki, T. and Takigawa, M. (2008) Novel 
transcription-factor-like function of human matrix metalloproteinase 
3 regulating the CTGF/CCN2 gene. Mol. Cell Biol. 28, 2391-2413. 
Fainardi, E., Castellazzi, M., Tamborino, C., Trentini, A., Manfrinato, 
M. C., Baldi, E., Tola, M. R., Dallocchio, F., Granieri, E. and Bellini, 
T. (2009) Potential relevance of cerebrospinal fl uid and serum lev-
els and intrathecal synthesis of active matrix metalloproteinase-2 
(MMP-2) as markers of disease remission in patients with multiple 
sclerosis. Mult. Scler. 15, 547-554. 
Forsyth, P. A., Wong, H., Laing, T. D., Rewcastle, N. B., Morris, D. G., 
Muzik, H., Leco, K. J., Johnston, R. N., Brasher, P. M., Sutherland, 
G. and Edwards, D. R. (1999) Gelatinase-A (MMP-2), gelatinase-B 
(MMP-9) and membrane type matrix metalloproteinase-1 (MT1-
MMP) are involved in different aspects of the pathophysiology of 
malignant gliomas. Br. J. Cancer. 79, 1828-1835.
Freise, C., Erben, U., Muche, M., Farndale, R., Zeitz, M., Somasunda-
ram, R. and Ruehl, M. (2009) The alpha 2 chain of collagen type 
VI sequesters latent proforms of matrix-metalloproteinases and 
modulates their activation and activity. Matrix Biol. 28, 480-489. 
Gasche, Y., Copin, J. C., Sugawara, T., Fujimura, M. and Chan, P. 
H. (2001) Matrix metalloproteinase inhibition prevents oxidative 
stress-associated blood-brain barrier disruption after transient fo-
cal cerebral ischemia. J. Cereb. Blood Flow Metab. 21, 1393-1400.
Gearing, A. J., Beckett, P., Christodoulou, M., Churchill, M., Clements, 
J., Davidson, A. H., Drummond, A. H., Galloway, W. A., Gilbert, R., 
Gordon, J. L., Gordon, J. L., Leber, T. M., Mangan, M., Miller, K., 
Nayee, P., Owen, K., Patel, S., Thomas, W., Wells, G., Wood, L. M. 
and Woolley, K. (1994) Processing of tumour necrosis factor-alpha 
precursor by metalloproteinases. Nature. 370, 555-557.
141
Kim and Joh.   Matrix Metalloproteinases in Neurodegenerative Diseases
www.biomolther.org
Giuliani, F., Fu, S. A., Metz, L. M. and Yong, V. W. (2005) Effective 
combination of minocycline and interferon-beta in a model of mul-
tiple sclerosis. J. Neuroimmunol. 165, 83-91.
Gross, J. and Lapiere, C, M. (1962) Collagenolytic activity in amphib-
ian tissues: a tissue culture assay. Proc. Natl. Acad. Sci. USA. 48, 
1014-1022.
Gu, Z., Cui, J., Brown, S., Fridman, R., Mobashery, S., Strongin, A. Y. 
and Lipton, S. A. (2005) A highly specifi c inhibitor of matrix metal-
loproteinase-9 rescues laminin from proteolysis and neurons from 
apoptosis in transient focal cerebral ischemia. J. Neurosci. 25, 
6401-6408.
Gu, Z., Kaul, M., Yan, B., Kridel, S. J., Cui, J., Strongin, A., Smith, J. 
W., Liddington, R. C. and Lipton, S. A. (2002) S-nitrosylation of ma-
trix metalloproteinases: signaling pathway to neuronal cell death. 
Science. 297, 1186-1190.
Hewson, A. K., Smith, T., Leonard, J. P. and Cuzner, M. L. (1995) Sup-
pression of experimental allergic encephalomyelitis in the Lewis 
rat by the matrix metalloproteinase inhibitor Ro31-9790. Infl amm. 
Res. 44, 345-349.
Horstmann, S., Budig, L., Gardner, H., Koziol, J., Deuschle, M., Schil-
ling, C. and Wagner, S. (2010) Matrix metalloproteinases in pe-
ripheral blood and cerebrospinal fl uid in patients with Alzheimer's 
disease. International psychogeriatrics / IPA 22: 966-972
Hu, J., Van den Steen, P. E., Sang, Q. X. and Opdenakker, G. (2007) 
Matrix metalloproteinase inhibitors as therapy for infl ammatory and 
vascular diseases. Nat. Rev. Drug Discov. 6, 480-498.
Ip, Y. C., Cheung, S. T. and Fan, S. T. (2007) Atypical localization of 
membrane type 1-matrix metalloproteinase in the nucleus is asso-
ciated with aggressive features of hepatocellular carcinoma. Mol. 
Carcinog. 46, 225-230.
Ishiguro, N., Ito, T., Obata, K., Fujimoto, N. and Iwata, H. (1996) De-
termination of stromelysin-1, 72 and 92 kDa type IV collagenase, 
tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in sy-
novial fl uid and serum from patients with rheumatoid arthritis. J. 
Rheumatol. 23, 1599-1604.
Ito, S., Kimura, K., Haneda, M., Ishida, Y., Sawada, M. and Isobe, K. 
(2007) Induction of matrix metalloproteinases (MMP3, MMP12 and 
MMP13) expression in the microglia by amyloid-beta stimulation 
via the PI3K/Akt pathway. Exp. Gerontol. 42, 532-537. 
Joo, S. H., Kwon, K. J., Kim, J. W., Kim, J. W., Hasan, M. R., Lee, H. 
J., Han, S. H. and Shin, C. Y. (2010) Regulation of matrix metal-
loproteinase-9 and tissue plasminogen activator activity by alpha-
synuclein in rat primary glial cells. Neurosci. Lett. 469, 352-356. 
Kheradmand, F., Werner, E., Tremble, P., Symons, M. and Werb, Z. 
(1998) Role of Rac1 and oxygen radicals in collagenase-1 expres-
sion induced by cell shape change. Science. 280, 898-902.
Kim, E. M. and Hwang, O. (2011) Role of matrix metalloproteinase-3 in 
neurodegeneration. J. Neurochem. 116, 22-32. 
Kim, K. S., Kim, H. Y., Joe, E. H. and Jou, I. (2008) Matrix metallopro-
teinase-3 induction in rat brain astrocytes: focus on the role of two 
AP-1 elements. Biochem. J. 410, 605-611.
Kim, Y. S., Choi, D. H., Block, M. L., Lorenzl, S., Yang, L., Kim, Y. 
J., Sugama, S., Cho, B. P., Hwang, O., Browne, S. E., Kim, S. Y., 
Hong, J. S., Beal, M. F. and Joh, T. H. (2007) A pivotal role of matrix 
metalloproteinase-3 activity in dopaminergic neuronal degenera-
tion via microglial activation. FASEB J. 21, 179-187. 
Kim, Y. S., Kim, S. S., Cho, J. J., Choi, D. H., Hwang, O., Shin, D. H., 
Chun, H. S., Beal, M. F. and Joh, T. H. (2005) Matrix metalloprotein-
ase-3: a novel signaling proteinase from apoptotic neuronal cells 
that activates microglia. J. Neurosci. 25, 3701-3711.
Korzus, E., Nagase, H., Rydell, R. and Travis, J. (1997) The mitogen-
activated protein kinase and JAK-STAT signaling pathways are re-
quired for an oncostatin M-responsive element-mediated activation 
of matrix metalloproteinase 1 gene expression. J. Biol. Chem. 272, 
1188-1196.
Kwan, J. A., Schulze, C. J., Wang, W., Leon, H., Sariahmetoglu, M., 
Sung, M., Sawicka, J., Sims, D. E., Sawicki, G. and Schulz, R. 
(2004) Matrix metalloproteinase-2 (MMP-2) is present in the nu-
cleus of cardiac myocytes and is capable of cleaving poly (ADP-
ribose) polymerase (PARP) in vitro. FASEB J. 18, 690-692. 
Larsen, P. H., DaSilva, A. G., Conant, K. and Yong, V. W. (2006) My-
elin formation during development of the CNS is delayed in matrix 
metalloproteinase-9 and -12 null mice. J. Neurosci. 26, 2207-2214.
Larsen, P. H., Wells, J. E., Stallcup, W. B., Opdenakker, G. and Yong, 
V. W. (2003) Matrix metalloproteinase-9 facilitates remyelination in 
part by processing the inhibitory NG2 proteoglycan. J. Neurosci. 
23, 11127-11135.
Lee, M. K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A. S., Dawson, 
T. M., Copeland, N. G., Jenkins, N. A. and Price, D. L. (2002) Hu-
man alpha-synuclein-harboring familial Parkinson's disease-linked 
Ala-53 --> Thr mutation causes neurodegenerative disease with 
alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. 
Sci. USA. 99, 8968-8973.
Lee, R., Kermani, P., Teng, K. K. and Hempstead, B. L. (2001) Regula-
tion of cell survival by secreted proneurotrophins. Science. 294, 
1945-1948.
Lee, S. R., Kim, H. Y., Rogowska, J., Zhao, B. Q., Bhide, P., Parent, J. 
M. and Lo, E. H. (2006) Involvement of matrix metalloproteinase in 
neuroblast cell migration from the subventricular zone after stroke. 
J. Neurosci. 26, 3491-3495.
Li, W., Chang, L., Rong, Z. and Liu, W. (2011) Retinoic aacid dimin-
ished the expression of MMP-2 in hyperoxia-exposed premature 
rat lung fi broblasts through regulating mitogen-activated protein 
kinases. J. Huazhong. Univ. Sci. Technolog. Med. Sci. 31, 251-257. 
Li, W., West, N., Colla, E., Pletnikova, O., Troncoso, J. C., Marsh, L., 
Dawson, T. M., Jäkälä, P., Hartmann, T., Price, D. L. and Lee, M. 
K. (2005) Aggregation promoting C-terminal truncation of alpha-
synuclein is a normal cellular process and is enhanced by the fa-
milial Parkinson's disease-linked mutations. Proc. Natl. Acad. Sci. 
USA. 102, 2162-2167. 
Limb, G. A., Matter, K., Murphy, G., Cambrey, A. D., Bishop, P. N., Mor-
ris, G. E. and Khaw, P. T. (2005) Matrix metalloproteinase-1 associ-
ates with intracellular organelles and confers resistance to lamin 
A/C degradation during apoptosis. Am. J. Pathol. 166, 1555-1563.
Liu, C. W., Giasson, B. I., Lewis, K. A., Lee, V. M., Demartino, G. N. 
and Thomas, P. J. (2005) A precipitating role for truncated alpha-
synuclein and the proteasome in alpha-synuclein aggregation: im-
plications for pathogenesis of Parkinson disease. J. Biol. Chem. 
280, 22670-22678. 
Liu, X., Manzano, G., Lovett, D. H. and Kim, H. T. (2010) Role of AP-1 
and RE-1 binding sites in matrix metalloproteinase-2 transcription-
al regulation in skeletal muscle atrophy. Biochem. Biophys. Res. 
Commun. 396, 219-223.
Lorenzl, S., Albers, D. S., Narr, S., Chirichigno, J. and Beal, M. F. 
(2002) Expression of MMP-2, MMP-9, and MMP-1 and their endog-
enous counterregulators TIMP-1 and TIMP-2 in postmortem brain 
tissue of Parkinson's disease. Exp. Neurol. 178, 13-20.
Lorenzl, S., Albers, D. S., Relkin, N., Ngyuen, T., Hilgenberg, S. L., 
Chirichigno, J., Cudkowicz, M. E. and Beal, M. F. (2003) Increased 
plasma levels of matrix metalloproteinase-9 in patients with Al-
zheimer's disease. Neurochem. Int. 43, 191-196.
Maeda, A. and Sobel, R. A. (1996) Matrix metalloproteinases in the 
normal human central nervous system, microglial nodules, and 
multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55, 300-
309.
Marchenko, N. D., Marchenko, G. N., Weinreb, R. N., Lindsey, J. D., 
Kyshtoobayeva, A., Crawford, H. C. and Strongin, A. Y. (2004) 
Beta-catenin regulates the gene of MMP-26, a novel metallopro-
teinase expressed both in carcinomas and normal epithelial cells. 
Int. J. Biochem. Cell. Biol. 36, 942-956.
Matrisian, L. M., Glaichenhaus, N., Gesnel, M. C. and Breathnach, R. 
(1985) Epidermal growth factor and oncogenes induce transcrip-
tion of the same cellular mRNA in rat fi broblasts. EMBO J. 4, 1435-
1440.
Matsuno, H., Yudoh, K., Watanabe, Y., Nakazawa, F., Aono, H. and 
Kimura, T. (2001) Stromelysin-1 (MMP-3) in synovial fl uid of pa-
tients with rheumatoid arthritis has potential to cleave membrane 
bound Fas ligand. J. Rheumatol. 28, 22-28.
McCarthy, S. M., Bove, P. F., Matthews, D. E., Akaike, T. and van der 
Vliet, A. (2008) Nitric oxide regulation of MMP-9 activation and its 
relationship to modifi cations of the cysteine switch. Biochemistry. 
47, 5832-5840.
McClain, J. A., Phillips, L. L. and Fillmore, H. L. (2009) Increased 
MMP-3 and CTGF expression during lipopolysaccharide-induced 
142
Biomol  Ther 20(2), 133-143 (2012)
http://dx.doi.org/10.4062/biomolther.2012.20.2.133
dopaminergic neurodegeneration. Neurosci. Lett. 460, 27-31. 
Meighan, S. E., Meighan, P. C., Choudhury, P., Davis, C. J., Olson, M. 
L., Zornes, P. A., Wright, J. W. and Harding, J. W. (2006) Effects of 
extracellular matrix-degrading proteases matrix metalloproteinases 
3 and 9 on spatial learning and synaptic plasticity. J. Neurochem. 
96, 1227-1241. 
Metz, L. M., Zhang, Y., Yeung, M., Patry, D. G., Bell, R. B., Stoian, C. 
A., Yong, V. W., Patten, S. B., Duquette, P., Antel, J. P. and Mitchell, 
J. R. (2004) Minocycline reduces gadolinium-enhancing magnetic 
resonance imaging lesions in multiple sclerosis. Ann. Neurol. 55, 
756.
Miller, D. W., Ahmad, R., Hague, S., Baptista, M. J., Canet-Aviles, R., 
McLendon, C., Carter, D. M., Zhu, P. P., Stadler, J., Chandran, J., 
Klinefelter, G. R. Blackstone, C. and Cookson, M. R. (2003) L166P 
mutant DJ-1, causative for recessive Parkinson's disease, is de-
graded through the ubiquitin-proteasome system. J. Biol. Chem. 
278, 36588-36595. 
Miners, J. S., Baig, S., Palmer, J., Palmer, L. E., Kehoe, P. G. and 
Love, S. (2008) Abeta-degrading enzymes in Alzheimer's disease. 
Brain Pathol. 18, 240-252.
Mohanam, S., Wang, S. W., Rayford, A., Yamamoto, M., Sawaya, R., 
Nakajima, M., Liotta, L. A., Nicolson, G. L., Stetler-Stevenson, W. 
G. and Rao, J. S. (1995) Expression of tissue inhibitors of metal-
loproteinases: negative regulators of human glioblastoma invasion 
in vivo. Clin. Exp. Metastasis. 13, 57-62.
Ogier, C., Bernard, A., Chollet, A. M., LE Diguardher, T., Hanessian, S., 
Charton, G., Khrestchatisky, M. and Rivera, S. (2006) Matrix metal-
loproteinase-2 (MMP-2) regulates astrocyte motility in connection 
with the actin cytoskeleton and integrins. Glia. 54, 272-284.
Ohnishi. S. and Takano, K. (2004) Amyloid fi brils from the viewpoint of 
protein folding. Cell Mol. Life Sci. 61, 511-524.
Okamoto, T., Akaike, T., Sawa, T., Miyamoto, Y., van der Vliet, A. 
and Maeda, H. (2001) Activation of matrix metalloproteinases by 
peroxynitrite-induced protein S-glutathiolation via disulfi de S-oxide 
formation. J. Biol. Chem. 276, 29596-29602.
Opdenakker, G., Dillen, C., Fiten, P., Martens, E., Van Aelst, I., Van 
den Steen, P. E., Nelissen, I., Starckx, S., Descamps, F. J., Hu, 
J., Piccard, H., Van Damme, J., Wormald, M. R., Rudd, P. M. and 
Dwek, R. A. (2006) Remnant epitopes, autoimmunity and glycosyl-
ation. Biochim. Biophys. Acta. 1760, 610-615. 
Osteen, K. G., Bruner, K. L. and Sharpe-Timms, K. L. (1996) Steroid 
and growth factor regulation of matrix metalloproteinase expres-
sion and endometriosis. Semin. Reprod. Endocrinol. 14, 247-255.
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., 
Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. 
S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, 
T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., 
Golbe, L. I. and Nussbaum, R. L. (1997) Mutation in the alpha-
synuclein gene identifi ed in families with Parkinson's disease. Sci-
ence. 276, 2045-2047.
Rao, J. S., Yamamoto, M., Mohaman, S., Gokaslan, Z. L., Fuller, G. 
N., Stetler-Stevenson, W. G., Rao, V. H., Liotta, L. A., Nicolson, G. 
L. and Sawaya, R. E. (1996) Expression and localization of 92 kDa 
type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin. 
Exp. Metastasis. 14, 12-18.
Reunanen, N., Westermarck, J., Häkkinen, L., Holmström, T. H., Elo, 
I., Eriksson, J. E. and Kähäri, V. M. (1998) Enhancement of fi bro-
blast collagenase (matrix metalloproteinase-1) gene expression by 
ceramide is mediated by extracellular signal-regulated and stress-
activated protein kinase pathways. J. Biol. Chem. 273, 5137-5145.
Ries, C. and Petrides, P. E. (1995) Cytokine regulation of matrix metal-
loproteinase activity and its regulatory dysfunction in disease. Biol. 
Chem. Hoppe. Seyler. 376, 345-355.
Roher, A. E., Kasunic, T. C., Woods, A. S., Cotter, R. J., Ball, M. J. and 
Fridman, R. (1994) Proteolysis of A beta peptide from Alzheimer 
disease brain by gelatinase A. Biochem Biophys Res Commun. 
205, 1755-1761.
Romanic, A. M., White, R. F., Arleth, A. J., Ohlstein, E. H. and Barone, 
F. C. (1998) Matrix metalloproteinase expression increases after 
cerebral focal ischemia in rats: inhibition of matrix metalloprotein-
ase-9 reduces infarct size. Stroke. 29, 1020-1030.
Rosenberg, G. A., Cunningham, L. A., Wallace, J., Alexander, S., Es-
trada, E. Y., Grossetete, M., Razhagi, A., Miller, K. and Gearing, A. 
(2001) Immunohistochemistry of matrix metalloproteinases in re-
perfusion injury to rat brain: activation of MMP-9 linked to stromely-
sin-1 and microglia in cell cultures. Brain Res. 893, 104-112.
Sang, Q. X., Jin, Y., Newcomer, R. G., Monroe, S. C., Fang, X., Hurst, 
D. R., Lee, S., Cao, Q. and Schwartz, M. A. (2006) Matrix metallo-
proteinase inhibitors as prospective agents for the prevention and 
treatment of cardiovascular and neoplastic diseases. Curr. Top. 
Med. Chem. 6, 289-316.
Sapolsky, A. I., Howell, D. S. and Woessner JF, Jr. (1974) Neutral pro-
teases and cathepsin D in human articular cartilage. The Journal of 
clinical investigation 53, 1044-1053
Sellebjerg, F. and Sørensen, T. L. (2003) Chemokines and matrix me-
talloproteinase-9 in leukocyte recruitment to the central nervous 
system. Brain Res. Bull. 61, 347-355.
Shin, E. J., Kim, E. M., Lee, J. A., Rhim, H. and Hwang, O. (2012) 
Matrix metalloproteinase-3 is activated by HtrA2/Omi in dopami-
nergic cells: Relevance to Parkinson's disease. Neurochem. Int. 
60, 249-256. 
Singh, N. K., Quyen, D. V., Kundumani-Sridharan, V., Brooks, P. C. 
and Rao, G. N. (2010) AP-1 (Fra-1/c-Jun)-mediated induction of 
expression of matrix metalloproteinase-2 is required for 15S-hy-
droxyeicosatetraenoic acid-induced angiogenesis. J. Biol. Chem. 
285, 16830-16843. 
Si-Tayeb, K., Monvoisin, A., Mazzocco, C., Lepreux, S., Decossas, M., 
Cubel, G., Taras, D., Blanc, J. F., Robinson, D. R. and Rosenbaum, 
J. (2006) Matrix metalloproteinase 3 is present in the cell nucleus 
and is involved in apoptosis. Am. J. Pathol. 169, 1390-1401.
Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, 
R. and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature. 
388, 839-840.
Starckx, S., Van den Steen, P. E., Verbeek, R., van Noort, J. M. and 
Opdenakker, G. (2003) A novel rationale for inhibition of gelatinase 
B in multiple sclerosis: MMP-9 destroys alpha B-crystallin and gen-
erates a promiscuous T cell epitope. J. Neuroimmunol. 141, 47-57.
Steffensen, B., Wallon, U. M. and Overall, C. M. (1995) Extracellu-
lar matrix binding properties of recombinant fi bronectin type II-like 
modules of human 72-kDa gelatinase/type IV collagenase. High 
affi nity binding to native type I collagen but not native type IV col-
lagen. J. Biol. Chem. 270, 11555-11566.
Stojic, J., Hagemann, C., Haas, S., Herbold, C., Kühnel, S., Gerngras, 
S., Roggendorf, W., Roosen, K. and Vince, G. H. (2008) Expres-
sion of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 
is correlated with the WHO-grading of human malignant gliomas. 
Neurosci. Res. 60, 40-49. 
Sung, J. Y., Park, S. M., Lee, C. H., Um, J. W., Lee, H. J., Kim, J., Oh, 
Y. J., Lee, S. T., Paik, S. R. and Chung, K. C. (2005) Proteolytic 
cleavage of extracellular secreted {alpha}-synuclein via matrix me-
talloproteinases. J. Biol. Chem. 280, 25216-25224. 
Sung, M. M., Schulz, C. G., Wang, W., Sawicki, G., Bautista-López, N. 
L. and Schulz, R. (2007) Matrix metalloproteinase-2 degrades the 
cytoskeletal protein alpha-actinin in peroxynitrite mediated myocar-
dial injury. J. Mol. Cell Cardiol. 43, 429-436. 
Szklarczyk, A., Lapinska, J., Rylski, M., McKay, R. D. and Kaczmarek, 
L. (2002) Matrix metalloproteinase-9 undergoes expression and 
activation during dendritic remodeling in adult hippocampus. J. 
Neurosci. 22, 920-930.
Tiraboschi, P., Hansen, L. A., Thal, L. J. and Corey-Bloom, J. (2004) 
The importance of neuritic plaques and tangles to the development 
and evolution of AD. Neurology. 62, 1984-1989.
Treadwell, B. V., Neidel, J., Pavia, M., Towle, C. A., Trice, M. E. and 
Mankin, H. J. (1986) Purifi cation and characterization of collage-
nase activator protein synthesized by articular cartilage. Arch. Bio-
chem. Biophys. 251, 715-723.
Uhm, J. H., Dooley, N. P., Villemure, J. G. and Yong, V. W. (1996) Gli-
oma invasion in vitro: regulation by matrix metalloprotease-2 and 
protein kinase C. Clin. Exp. Metastasis. 14, 421-433.
Ulisse, S., Farina, A. R., Piersanti, D., Tiberio, A., Cappabianca, L., 
D'Orazi, G., Jannini, E. A., Malykh, O., Stetler-Stevenson, W. G. 
and D'Armiento, M. (1994) Follicle-stimulating hormone increases 
the expression of tissue inhibitors of metalloproteinases TIMP-1 
and TIMP-2 and induces TIMP-1 AP-1 site binding complex(es) in 
143
Kim and Joh.   Matrix Metalloproteinases in Neurodegenerative Diseases
www.biomolther.org
prepubertal rat Sertoli cells. Endocrinology. 135, 2479-2487.
Vaillant, C., Meissirel, C., Mutin, M., Belin, M. F., Lund, L. R. and 
Thomasset, N. (2003) MMP-9 defi ciency affects axonal outgrowth, 
migration, and apoptosis in the developing cerebellum. Mol. Cell 
Neurosci. 24, 395-408.
Van den Steen, P. E., Van Aelst, I., Hvidberg, V., Piccard, H., Fiten, P., 
Jacobsen, C., Moestrup, S. K., Fry, S., Royle, L., Wormald, M. R., 
Wallis, R., Rudd, P. M., Dwek, R. A. and Opdenakker, G. (2006) 
The hemopexin and O-glycosylated domains tune gelatinase B/
MMP-9 bioavailability via inhibition and binding to cargo receptors. 
J. Biol. Chem. 281, 18626-18637. 
Van Lint, P. and Libert, C. (2007) Chemokine and cytokine processing 
by matrix metalloproteinases and its effect on leukocyte migration 
and infl ammation. J. Leukoc. Biol. 82, 1375-1381. 
Van Wart, H. E. and Birkedal-Hansen, H. (1990) The cysteine switch: 
a principle of regulation of metalloproteinase activity with poten-
tial applicability to the entire matrix metalloproteinase gene family. 
Proc. Natl. Acad. Sci. USA. 87, 5578-5582.
Vincenti, M. P. (2001) The matrix metalloproteinase (MMP) and tissue 
inhibitor of metalloproteinase (TIMP) genes. (2001) Transcriptional 
and posttranscriptional regulation, signal transduction and cell-
type-specifi c expression. Methods Mol. Biol. 151, 121-148.
Vincenti, M. P. and Brinckerhoff, C. E. (2007) Signal transduction and 
cell-type specifi c regulation of matrix metalloproteinase gene ex-
pression: can MMPs be good for you? J. Cell Physiol. 213, 355-
364.
Walker, E. J. and Rosenberg, G. A. (2010) Divergent role for MMP-2 
in myelin breakdown and oligodendrocyte death following transient 
global ischemia. J. Neurosci. Res. 88, 764-773.
Wang, W., Sawicki, G. and Schulz, R. (2002a) Peroxynitrite-induced 
myocardial injury is mediated through matrix metalloproteinase-2. 
Cardiovasc. Res. 53, 165-174.
Wang, W., Schulze, C. J., Suarez-Pinzon, W. L., Dyck, J. R., Sawicki, 
G. and Schulz, R. (2002b) Intracellular action of matrix metallopro-
teinase-2 accounts for acute myocardial ischemia and reperfusion 
injury. Circulation. 106, 1543-1549.
Waubant, E., Goodkin, D. E., Gee, L., Bacchetti, P., Sloan, R., Stewart, 
T., Andersson, P. B., Stabler, G. and Miller, K. (1999) Serum MMP-9 
and TIMP-1 levels are related to MRI activity in relapsing multiple 
sclerosis. Neurology. 53, 1397-1401.
Wenk, G. L. (2003) Neuropathologic changes in Alzheimer's disease. 
J. Clin. Psychiatry. 64(Suppl 9), 7-10.
Werb, Z. and Reynolds, J. J. (1974) Stimulation by endocytosis of the 
secretion of collagenase and neutral proteinase from rabbit syno-
vial fi broblasts. J. Exp. Med. 140, 1482-1497.
Woo, M. S., Park, J. S., Choi, I. Y., Kim, W. K. and Kim, H. S. (2008) 
Inhibition of MMP-3 or -9 suppresses lipopolysaccharide-induced 
expression of proinfl ammatory cytokines and iNOS in microglia. J. 
Neurochem. 106, 770-780.
Yamamoto, M., Hirayama, R., Naruse, K., Yoshino, K., Shimada, A., In-
oue, S., Kayagaki, N., Yagita, H., Okumura, K. and Ikeda, S. (1999) 
Structure-activity relationship of hydroxamate-based inhibitors on 
membrane-bound Fas ligand and TNF-alpha processing. Drug 
Des. Discov. 16, 119-130.
Yamamoto, M., Mohanam, S., Sawaya, R., Fuller, G. N., Seiki, M., 
Sato, H., Gokaslan, Z. L., Liotta, L. A., Nicolson, G. L. and Rao, J. 
S. (1996) Differential expression of membrane-type matrix metal-
loproteinase and its correlation with gelatinase A activation in hu-
man malignant brain tumors in vivo and in vitro. Cancer Res. 56, 
384-392.
Yan, C. and Boyd, D. D. (2007) Regulation of matrix metalloproteinase 
gene expression. J. Cell Physiol. 211, 19-26.
Yan, P., Hu, X., Song, H., Yin, K., Bateman, R. J., Cirrito, J. R., Xiao, 
Q., Hsu, F. F., Turk, J. W., Xu, J., Hsu, C. Y., Holtzman, D. M. and 
Lee, J. M. (2006) Matrix metalloproteinase-9 degrades amyloid-
beta fi brils in vitro and compact plaques in situ. J. Biol. Chem. 281, 
24566-24574. 
Yan, W., Zhang, W., Sun, L., Liu, Y., You, G., Wang, Y., Kang, C., You, 
Y. and Jiang, T. (2011) Identifi cation of MMP-9 specifi c microRNA 
expression profi le as potential targets of anti-invasion therapy in 
glioblastoma multiforme. Brain Res. 1411, 108-115. 
Yang, Y., Candelario-Jalil, E., Thompson, J. F., Cuadrado, E., Estra-
da, E. Y., Rosell, A., Montaner, J. and Rosenberg, G. A. (2010) 
Increased intranuclear matrix metalloproteinase activity in neurons 
interferes with oxidative DNA repair in focal cerebral ischemia. J. 
Neurochem. 112, 134-149. 
Yang, Y., Estrada, E. Y., Thompson, J. F., Liu, W. and Rosenberg, G. 
A. (2007) Matrix metalloproteinase-mediated disruption of tight 
junction proteins in cerebral vessels is reversed by synthetic matrix 
metalloproteinase inhibitor in focal ischemia in rat. J. Cereb. Blood 
Flow Metab. 27, 697-709. 
Ye, H., Cai, P. C., Zhou, Q. and Ma, W. L. (2011) Transforming growth 
factor-β1 suppresses the up-regulation of matrix metalloprotein-
ase-2 by lung fi broblasts in response to tumor necrosis factor-α. 
Wound Repair Regen. 19, 392-399. 
Yong, V. W. (2005) Metalloproteinases: mediators of pathology and 
regeneration in the CNS. Nat. Rev. Neurosci. 6, 931-944.
Yong, V. W., Krekoski, C. A., Forsyth, P. A., Bell, R. and Edwards, D. R. 
(1998) Matrix metalloproteinases and diseases of the CNS. Trends 
Neurosci. 21, 75-80. 
Yong, V. W., Zabad, R. K., Agrawal, S., Goncalves Dasilva, A. and 
Metz, L. M. (2007) Elevation of matrix metalloproteinases (MMPs) 
in multiple sclerosis and impact of immunomodulators. J. Neurol. 
Sci. 259, 79-84. 
Yoshida, D., Watanabe, K., Takahashi, H., Sugisaki, Y. and Teramoto, 
A. (2003) Apoptotic induction by BE16627B on human malignant 
glioma cell lines by an anti-matrix metalloproteinase agent. Brain 
Tumor Pathol. 20, 13-19.
Yoshiyama, Y., Asahina, M. and Hattori, T. (2000) Selective distribu-
tion of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease 
brain. Acta. Neuropathol. 99, 91-95.
Yushchenko, M., Weber, F., Mäder, M., Schöll, U., Maliszewska, M., 
Tumani, H., Felgenhauer, K. and Beuche, W. (2000) Matrix me-
talloproteinase-9 (MMP-9) in human cerebrospinal fl uid (CSF): 
elevated levels are primarily related to CSF cell count. J. Neuroim-
munol. 110, 244-251.
Zucker, S., Lysik, R. M., Zarrabi, M. H., Greenwald, R. A., Gruber, 
B., Tickle, S. P., Baker, T. S. and Docherty, A. J. (1994) Elevated 
plasma stromelysin levels in arthritis. J. Rheumatol. 21, 2329-2333.
